TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06601504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-760 planned dose 1
Description: HMPL-760 planned dose 1 daily (QD) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-GemOx
Description: R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R-GemOx
Description: R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-GemOx
Description: R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R-GemOx
Description: R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMPL-760 placebo planned dose 1
Description: HMPL-760 placebo planned dose 1 daily (QD) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-760 planned dose 2
Description: HMPL-760 planned dose 2 daily (QD) orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMPL-760 placebo planned dose 2
Description: HMPL-760 placebo planned dose 2 daily (QD) orally
Study: NCT06614270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK cells
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) on day -5, -4, and -3. Doses of 2×10\^6/kg, 3×10\^6/kg, 4×10\^6/kg anti-CD19 CAR-NK cells will be infused in each group on Day 0, 7, and 14 using the \&#34;3 + 3\&#34; dose-escalation strategy.
Study: NCT05585346

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MLS laser
Description: Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLS laser
Description: Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral vitamin B1
Description: Oral vitamin B1 10mg, times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral vitamin B1
Description: Oral vitamin B1 10mg, times/day
Study: NCT05009862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: rivaroxaban 2.5 milligrams twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: aspirin 81 milligrams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81Mg Ec Tab
Description: aspirin 81 milligrams
Study: NCT06697301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIK1001
Description: EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIK1001
Description: EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab (KEYTRUDA® )
Description: Pembrolizumab is a PD-1 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA® )
Description: Pembrolizumab is a PD-1 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA® )
Description: Pembrolizumab is a PD-1 inhibitor.
Study: NCT06699264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training
Description: Pressure cuff is applied to the leg during training for low-load strength training with simultaneous restiction of blood flow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training without BFR
Description: Strength training according to experimentral group without simultaneous restriction blood flow
Study: NCT06698848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamin
Description: Participants in this study will have been diagnosed with major depressive episode (MDE) and have not received any psychiatric treatment for at least 2 weeks (5 weeks if on fluoxetine).Patients will receive intravenous ketamine as the only study drug treatment for the 2 weeks of the study. Magnetic Resonance Imaging (MRI) will be used to measure effects of ketamine on brain structure, function and chemistry, in addition to a soft-nasal brushing procedure to obtain olfactory sensory neurons which will provide the ability to profile in vivo how neurons may react to KET treatment in depressed patients.
Study: NCT06698926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-616
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet
Study: NCT05082766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enhanced DefenAge 8-in-1 BioSerum
Description: DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
Study: NCT05232292

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrix Quadri
Description: vaccination by Ultrix Quadri against flu
Study: NCT05367050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lucid Lane Therapy Program
Description: This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lucid Lane Therapy Program
Description: This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Preparedness Course
Description: This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
Study: NCT06443411

Intervention type: OTHER
Intervention: Monitoring of cerebral hemodynamics
Description: A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.

Intervention type: OTHER
Intervention: Monitoring of cerebral hemodynamics
Description: A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.
Study: NCT06698926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Capsule
Study: NCT06698575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1179
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1179
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-1179
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-1179
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1179
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1179 Placebo
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1179 Placebo
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
Study: NCT06120192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano
Description: Receives the piano training
Study: NCT04443868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide-Releasing Drug
Description: Nasal Spray + Nasal Irrigation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitric Oxide-Releasing Drug
Description: Nasal Spray + Nasal Irrigation
Study: NCT04915872

Intervention type: PROCEDURE
Intervention: Blood sampling (T0, inclusion)
Description: Blood sample (5 ml) at 30 minutes after the loading dose of 4g/0.5g over 30 minutes for therapeutic drug monitoring at peak concentration (Cmax)

Intervention type: PROCEDURE
Intervention: other samplings (T1)
Description: - T1 : Day of the first surgical revision, under PTZ administered by continuous infusion : Blood sample (5 ml) for therapeutic drug monitoring at steady state concentration (Css).~Urinary sample and collection of urinary volume between T0 and T1 (Urinary Clearance) NPT fluid sample and collection of NPT volume between T0 and T1 (Peritoneal Clearance) Peritoneal sampling for therapeutic drug monitoring at the site of infection (CPt)
Study: NCT05318170

Intervention type: PROCEDURE
Intervention: Laparoscopic ultra-radical lymph node debulking
Description: Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
Study: NCT06698575

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-1179 Placebo
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-1179 Placebo
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1179 Placebo
Description: Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
Study: NCT05147532

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714
Description: PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
Study: NCT04524390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: A small molecule inhibitor of the ileal bile acid transporter (IBAT)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to maralixibat except for the active drug substance
Study: NCT06127953

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intermediate cleft rhinoplasty
Description: intermediate cleft rhinoplasty using open approach and combined techniques of Tajima, Dibbell and Potter's Rhinoplasty
Study: NCT05230303

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Description: Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
Study: NCT06259747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acutaping
Description: Application of the kinesio tape on finger and forearm flexor tape after localization of the acupoints of application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxylamine and Pyridoxine
Description: traditional medical treatment for nausea and vomiting during pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxylamine and Pyridoxine
Description: traditional medical treatment for nausea and vomiting during pregnancy
Study: NCT06302608

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT001
Description: Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT001
Description: Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration
Study: NCT05984966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Employment
Description: PeerC2T is part of a supported employment program where PWID are trained and supported to provide PWID with job skills to be able to act as Peer Health Worker to facilitate distribution of rapid SARS-CoV-2 testing to other PWID. The effect of the training on the Peer Health Worker themself will be evaluated (Aim 1). In addition, in Aim 2 they will distribute the rapid test kits in places of residence such as tents, shelters, apartments, trailers, or houses or locations where other PWID frequently engage with services such as syringe exchange. The kit is the BinaxNOW COVID-19 Antigen Self Test, which is approved to be used as a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. PWID community members will be offered a free test kit, and the Peer Health Worker will record whether the community member elected to take the test (yes/no), and they will also collect administrative demographic data on the PWID.
Study: NCT05719766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education ,psycological support and social support
Description: we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire
Study: NCT06243328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: negative wound pressure therapy
Description: nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
Study: NCT04376424

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hand Held Ultrasound
Description: Guideline directed medical therapy for heart failure with the addition of hand held ultrasound
Study: NCT06699238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Standard conventional exercise for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Standard conventional exercise for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise group performed the following training: warm-up for 5 min, walking for 20 min at an intensity that would use 60-70% of the HR reserve, and cool down for 5 min. Additionally, they performed standard conventional exercises at home for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.The aerobic exercise group performed on a treadmill under the supervision of a physician.
Study: NCT06699446

Intervention type: OTHER
Group type: OTHER
Intervention: pre rehabilitation
Description: preoperative pre-rehabilitation (respiratory training, exercise therapy). Establish an individualized rehabilitation plan and postoperative communication via telephone or app

Intervention type: OTHER
Group type: OTHER
Intervention: pre rehabilitation
Description: preoperative pre-rehabilitation (respiratory training, exercise therapy). Establish an individualized rehabilitation plan and postoperative communication via telephone or app
Study: NCT05156905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab
Description: Cirmtuzumab will be given in combination with docetaxel.
Study: NCT04591951

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I2-ART
Description: Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Care as usual
Study: NCT06389799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: PD-1 inhibitor, Intravenous infusion
Study: NCT05744180

Intervention type: OTHER
Group type: OTHER
Intervention: Interventional
Description: The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
Study: NCT05918744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Participants will extend their time in bed by one hour for 2 weeks while being monitored.